Saturday, 5 September 2026European Markets

FAYENC.SARREGUEMI. Stock Was Up By 18.23% On Thursday

Loading stream...

(vianews) - the market ended the session with fayenc.sarreguemi. (faye.pa) rising 18.23% to €21.40 on thursday, after five successive sessions in a row of losses. cac 40 rose 0.01% to €8,205.81, after two consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.

fayenc.sarreguemi.'s last close was €18.10, 9.5% under its 52-week high of €20.00.

about fayenc.sarreguemi.

fayenceries de sarreguemines, digoin & vitry-le-francois société anonyme engages in ceramics business. the company provides bathroom fixtures and tiling, traditional and contemporary earthenware dishes, ceramic lighting fixtures, and hotel porcelain. it also exports its products. the company is headquartered in paris, france.

earnings per share

as for profitability, fayenc.sarreguemi. has a trailing twelve months eps of €-1.57.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -24.74%.

moving average

fayenc.sarreguemi.'s value is way higher than its 50-day moving average of €15.55 and way above its 200-day moving average of €18.88.

more news about fayenc.sarreguemi. (faye.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com